Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

被引：3

作者：

Kelly, Kevin R. ^{[1
]}

Chanan-Khan, Asher ^{[2
]}

Heffner, Leonard T. ^{[3
]}

Somlo, George ^{[4
]}

Siegel, David S. ^{[5
]}

Zimmerman, Todd ^{[6
]}

Karnad, Anand ^{[7
]}

Munshi, Nikhil C. ^{[8
]}

Jagannath, Sundar ^{[9
]}

Greenberg, Allen L. ^{[10
]}

Lonial, Sagar ^{[3
]}

Roy, Vivek ^{[2
]}

Ailawadhi, Sikander ^{[2
]}

Barmaki-Rad, Farima ^{[11
]}

Chavan, Shailesh ^{[12
]}

Patel, Pankaj ^{[12
]}

Wartenberg-Demand, Andrea ^{[11
]}

Haeder, Thomas ^{[11
]}

Anderson, Kenneth C. ^{[13
]}

机构：

[1] Univ So Calif, Los Angeles, CA USA

[2] Mayo Clin, Jacksonville, FL 32224 USA

[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[4] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[5] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[6] Univ Chicago Med, Chicago, IL USA

[7] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

[8] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[9] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[10] Mem Canc Inst, Pembroke Pines, FL USA

[11] Biotest AG, Dreieich, Germany

[12] Biotest Pharmaceut Corp, Boca Raton, FL USA

[13] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma
Kelly, Kevin R.
Siegel, David S.
Chanan-Khan, Asher A.
Somlo, George
Heffner, Leonard T.
Jagannath, Sundar
Zimmerman, Todd
Munshi, Nikhil C.
Madan, Sumit
Mohrbacher, Ann
Lonial, Sagar
Barmaki-Rad, Farima
Ruhle, Markus
Herrmann, Eva
Wartenberg-Demand, Andrea
Haeder, Thomas
Anderson, Kenneth C.
BLOOD, 2016, 128 (22)
[2] Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients
Kelly, Kevin R.
Chanan-Khan, Asher
Somlo, George
Heffner, Leonard T.
Siegel, David S.
Zimmerman, Todd M.
Jagannath, Sundar
Munshi, Nikhil C.
Lonial, Sagar
Roy, Vivek
Ruehle, Markus
Chavan, Shailesh
Patel, Pankaj
Rothenburger, Markus
Wartenberg-Demand, Andrea
Haeder, Thomas
Anderson, Kenneth C.
BLOOD, 2013, 122 (21)
[3] Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Jagannath, Sundar
Heffner, Leonard T., Jr.
Ailawadhi, Sikander
Munshi, Nikhil C.
Zimmerman, Todd M.
Rosenblatt, Jacalyn
Lonial, Sagar
Chanan-Khan, Asher
Ruehle, Markus
Rharbaoui, Faiza
Haeder, Thomas
Wartenberg-Demand, Andrea
Anderson, Kenneth C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (06): : 372 - 380
[4] Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Schoenfeld, Kurt
Zuber, Chantal
Pinkas, Jan
Haeder, Thomas
Bernoester, Katrin
Uherek, Christoph
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
[5] Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Kurt Schönfeld
Chantal Zuber
Jan Pinkas
Thomas Häder
Katrin Bernöster
Christoph Uherek
Journal of Hematology & Oncology, 10
[6] Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma
Wang, Chunling
He, Zhengmei
Shi, Yuye
Zhang, Lijuan
Chen, Yue
Chen, Zhi
Yu, Liang
HEMATOLOGY, 2017, 22 (02) : 88 - 92
[7] Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Lonial, Sagar
Vij, Ravi
Harousseau, Jean-Luc
Facon, Thierry
Moreau, Philippe
Mazumder, Amitabha
Kaufman, Jonathan L.
Leleu, Xavier
Tsao, L. Claire
Westland, Christopher
Singhal, Anil K.
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1953 - 1959
[8] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Lonial, Sagar
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raab, Marc S.
Facon, Thierry
Vij, Ravi
Moreau, Philippe
Reece, Donna E.
White, Darrell J.
Benboubker, Lotfi
Zonder, Jeffrey A.
Rossi, Jean-Francois
Tsao, Claire
Parli, Teresa
Kroog, Glenn
Singhal, Anil K.
Richardson, Paul G.
BLOOD, 2011, 118 (21) : 141 - 142
[9] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Paludo, Jonas
Mikhael, Joseph R.
LaPlant, Betsy R.
Halvorson, Alese E.
Kumar, Shaji
Gertz, Morie A.
Hayman, Suzanne R.
Buadi, Francis K.
Dispenzieri, Angela
Lust, John A.
Kapoor, Prashant
Leung, Nelson
Russell, Stephen J.
Dingli, David
Go, Ronald S.
Lin, Yi
Gonsalves, Wilson I.
Fonseca, Rafael
Bergsagel, P. Leif
Roy, Vivek
Sher, Taimur
Chanan-Khan, Asher A.
Ailawadhi, Sikander
Stewart, A. Keith
Reeder, Craig B.
Richardson, Paul G.
Rajkumar, S. Vincent
Lacy, Martha Q.
BLOOD, 2017, 130 (10) : 1198 - 1204
[10] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
Kobayashi, Tsutomu
Kuroda, Junya
Fuchida, Shin-ichi
Kaneko, Hitomi
Yagi, Hideo
Shibayama, Hirohiko
Tanaka, Hirokazu
Kosugi, Satoru
Uoshima, Nobuhiko
Kobayashi, Masayuki
Adachi, Yoko
Ohta, Kensuke
Ishii, Kazuyoshi
Uchiyama, Hitoji
Matsuda, Mitsuhiro
Nakatani, Eiji
Tsudo, Mitsuru
Shimazaki, Chihiro
Takaori-Kondo, Akifumi
Nomura, Shosaku
Matsumura, Itaru
Taniwaki, Masafumi
Kanakura, Yuzuru
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (01) : 37 - 45

← 1 2 3 4 5 →